- Home
- NAAS vs ACXP Comparison
NAAS vs ACXP Comparison
Compare NAAS & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- ACXP
- Stock Information
- Founded
- NAAS 2019
- ACXP 2017
- Country
- NAAS China
- ACXP United States
- Employees
- NAAS N/A
- ACXP N/A
- Industry
- NAAS Other Specialty Stores
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- ACXP Health Care
- Exchange
- NAAS Nasdaq
- ACXP Nasdaq
- Market Cap
- NAAS 8.3M
- ACXP 8.4M
- IPO Year
- NAAS 2017
- ACXP 2021
- Fundamental
- Price
- NAAS $1.32
- ACXP $0.37
- Analyst Decision
- NAAS
- ACXP Strong Buy
- Analyst Count
- NAAS 0
- ACXP 2
- Target Price
- NAAS N/A
- ACXP $10.00
- AVG Volume (30 Days)
- NAAS 1.3M
- ACXP 142.6K
- Earning Date
- NAAS 05-27-2025
- ACXP 05-13-2025
- Dividend Yield
- NAAS N/A
- ACXP N/A
- EPS Growth
- NAAS N/A
- ACXP N/A
- EPS
- NAAS N/A
- ACXP N/A
- Revenue
- NAAS $43,258,393.00
- ACXP N/A
- Revenue This Year
- NAAS $19.53
- ACXP N/A
- Revenue Next Year
- NAAS $151.36
- ACXP N/A
- P/E Ratio
- NAAS N/A
- ACXP N/A
- Revenue Growth
- NAAS 50.34
- ACXP N/A
- 52 Week Low
- NAAS $1.23
- ACXP $0.30
- 52 Week High
- NAAS $76.80
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- NAAS 32.24
- ACXP 45.53
- Support Level
- NAAS $1.18
- ACXP $0.34
- Resistance Level
- NAAS $1.39
- ACXP $0.43
- Average True Range (ATR)
- NAAS 0.24
- ACXP 0.03
- MACD
- NAAS 0.07
- ACXP 0.00
- Stochastic Oscillator
- NAAS 6.06
- ACXP 32.45
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.